Neuropsychologic status in multiple sclerosis after treatment with glatiramer.
about
Pharmacological treatment for memory disorder in multiple sclerosisGlatiramer acetate for multiple sclerosisPharmacologic treatment for memory disorder in multiple sclerosisCognitive impairment in multiple sclerosisTreatment of cognitive impairment in patients with multiple sclerosisImpact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational studyImmunomodulatory drugs for multiple sclerosis: a systematic review of clinical and cost effectiveness.Cognitive impairments in multiple sclerosis: a review.Therapeutic strategies for relapsing-remitting multiple sclerosis: a special focus on reduction of grey matter damage as measured by brain atrophy.Cognitive changes in multiple sclerosis.Visual memory in patients after anterior right temporal lobectomy and adult normative data for the Brown Location Test.A new measure of visual location learning and memory: development and psychometric properties for the Brown Location Test (BLT).Disease progression in pediatric multiple sclerosis: disparities between physical and neurocognitive outcomes.Cognitive dysfunction in multiple sclerosis.Longitudinal evaluation of cognitive functioning in pediatric multiple sclerosis: report from the US Pediatric Multiple Sclerosis Network.Quality of life in multiple sclerosis.When to initiate disease-modifying drugs for relapsing remitting multiple sclerosis in adults?Symptomatic therapy and rehabilitation in primary progressive multiple sclerosisThe neuropsychiatry of multiple sclerosis.Interferon-beta1a treatment for multiple sclerosis.Significance of neutralizing antibodies to interferon beta during treatment of multiple sclerosis: expert opinions based on the Proceedings of an International Consensus Conference.Introducing demographic corrections for the 10/36 Spatial Recall Test.Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis.Treatment of neuropsychiatric conditions associated with multiple sclerosis.Improvement of neuropsychological function in cognitively impaired multiple sclerosis patients treated with natalizumab: a preliminary study.Cognitive dysfunction in multiple sclerosis: the effect of pharmacological interventions.Assessment and rehabilitation of cognitive impairment in multiple sclerosis.Quality of life in multiple sclerosis: effects of current treatment options.Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence.Management of children with multiple sclerosis.Treatment of cognitive impairment in multiple sclerosis: position paper.Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study.Neuropsychological correlates of multiple sclerosis across the lifespan.Impact of Pharmacotherapy on Cognitive Dysfunction in Patients with Multiple Sclerosis.Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial.Immunomodulatory treatments and cognition in MS.Cognitive deficits in pediatric-onset multiple sclerosis: what does the future hold?Computer-assisted cognitive rehabilitation of attention deficits for multiple sclerosis: a randomized trial with fMRI correlates.One-year cyclophosphamide treatment combined with methylprednisolone improves cognitive dysfunction in progressive forms of multiple sclerosis.White Matter Diffusion Changes during the First Year of Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis.
P2860
Q24201735-FFFE457B-34B6-4B49-A244-26F3ABE91BBEQ24235498-4E0FD2E5-F504-4B98-9E2B-2AE59D66E72EQ24236019-6548DF85-F1B7-478F-BE44-14D74836161CQ28270988-935F3924-A86E-4FBC-9E46-29208634C622Q28272736-6E5FCD74-32E4-4255-8F3F-58CBADB7D81DQ28730321-91E67F80-7A41-41E6-BAE1-142E559F62ADQ30666435-396E04AA-6A6D-4F57-8028-626425BFC485Q30671631-8DF1D092-2D73-4ED2-B7EB-5585079AA299Q30869048-C00235B6-7698-459E-BDD3-F26C5D7CF58AQ33377548-07C12441-E081-4B2B-874A-DA2E8D30CFC3Q33522507-99F1E3C6-56D7-4B48-96E6-3F3C7AD06BABQ33575564-6E787CE6-162A-413C-AE83-C8B47560FB5FQ33837301-BD1CD0CC-7A12-48BA-AF71-C72DABD61A18Q34288839-BDF5E3CE-ED4E-4A63-A7FC-BF0AAA84D014Q34315953-6979EF96-B6AA-48AF-A3E0-DCD0DF222A2CQ34481312-E82CC315-BA5F-4F8C-B631-6339E7FCAA18Q35374052-01EEA081-241D-4209-B2A7-BD60284E2044Q35377529-66E954F5-047D-40A1-B27C-DA266702EDA1Q35752725-09FBAF66-4A07-40DB-9D21-FCCBAC45273BQ36106748-7CAC59AA-052D-4A70-A989-9A9CE5E19D46Q36212328-2AE2CD93-E65A-4F91-9026-43473ECE616BQ36578190-B3CA7BD9-D90E-4388-A088-4F8D80E4012EQ36613378-883DA185-4A79-43DF-B26C-FB387910F4E0Q36641533-EE257E7A-AF3D-43E8-BBBE-F52A56C90CB6Q37442275-BC261570-51AA-4CA5-8712-FC64C7E653F3Q37707371-8ADF88F0-8A00-4DE4-88FF-D3022C2A8F28Q37710114-B99EA28D-1515-44F3-983C-15D023A9C5EDQ37710122-D888C3AF-E9B8-4F16-A9A2-5C8571DE7BBDQ37976344-745ADFC4-EF72-4FB3-BC25-5AE892A1C621Q38002113-7046410F-68F7-404A-B6CE-85F977C31F08Q38062466-328BFFD4-B222-425A-A8D1-ECBE8B907C0EQ38377029-75E14C28-B63F-4BDD-BAE8-D39857D5FE79Q38545084-F401C2FC-EFA5-4480-8A45-7EB07654909CQ38736551-1F78BD7A-1CC1-4297-8911-FBD70D6ED954Q38937798-629ECCC7-2E02-4FFC-8D00-295C96638DFAQ38942635-E22EF0A4-EC3E-4774-A51B-3C394E644681Q39191862-B17E130A-B75A-46B6-976A-45C92F606C81Q45825551-7E93F4D9-BDCC-4FDC-B208-D4F8EDB79B4EQ46548047-34FFF796-190D-4A95-B4D6-51D4A4E4E3E2Q48845593-CA77BDA3-BEF0-4117-9706-B3F2D580C7D2
P2860
Neuropsychologic status in multiple sclerosis after treatment with glatiramer.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Neuropsychologic status in multiple sclerosis after treatment with glatiramer.
@en
type
label
Neuropsychologic status in multiple sclerosis after treatment with glatiramer.
@en
prefLabel
Neuropsychologic status in multiple sclerosis after treatment with glatiramer.
@en
P2093
P1433
P1476
Neuropsychologic status in multiple sclerosis after treatment with glatiramer.
@en
P2093
Goodman AD
McDermott MP
Schiffer RB
Weinstein A
P304
P356
10.1001/ARCHNEUR.56.3.319
P577
1999-03-01T00:00:00Z